Chemically modified short interfering hybrids (siHybrids): Nanoimmunoliposome delivery in vitro and in vivo for RNAi of HER-2

Nucleosides, Nucleotides and Nucleic Acids

Volumn 25, Issue 8, 2006, Pages 889-907

  Hogrefe, Richard ^a   Lebedev, Alexandre ^a   Zon, Gerald ^a,c   Pirollo, Kathleen ^b   Rait, Antonina ^b   Zhou, Qi ^b   Yu, Wei ^b   Chang, Esther ^b  

^a TriLink BioTechnologies Inc   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c APPLIED BIOSYSTEMS   (United States)

Author keywords

Chemically modified hybrid; DNA RNA hybrid; HER 2; Nanoimmunoliposome delivery; PANC 1; Pancreatic cancer cell line; RNAi; Short interfering RNA; Synthesis

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; 2' O METHYLRIBONUCLEOTIDE; COMPLEMENTARY RNA; DEOXYINOSINE; DIOLEOYLPHOSPHATIDYLETHANOLAMINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMMUNOLIPOSOME; MESSENGER RNA; RIBONUCLEASE H; RIBONUCLEOTIDE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL GROWTH; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFECT; ENCAPSULATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IC 50; MOUSE; NONHUMAN; PANCREAS CELL; PROTEIN EXPRESSION; RNA CLEAVAGE; RNA INTERFERENCE; TEMPERATURE SENSITIVITY;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CARCINOMA; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; LIPOSOMES; MICE; NANOSTRUCTURES; PANCREAS; RECEPTOR, ERBB-2; RECEPTORS, TRANSFERRIN; RNA INTERFERENCE; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33746786005     PISSN: 15257770     EISSN: 15322335     Source Type: Journal    
DOI: 10.1080/15257770600793885     Document Type: Article

References (54)

1. Leung, R.K.; Whittaker, P.A. RNA Interference: From Gene Silencing to Gene-Specific Therapeutics. Pharmacology & Therapeutics 2005, 107, 222-239.
2. Dorsett, Y.; Tuschl, T. siRNAs: Applications in Functional Genomics and Potential as Therapeutics. Nature Reviews Drug Discovery 2004, 3, 318-329.
3. Crooke, S.T. Antisense Strategies. Current Molecular Medicine 2004, 4, 465-487.
4. Kurreck, J. Antisense Technologies. Improvement through Novel Chemical Modifications. European Journal of Biochemistry 2003, 270, 1628-1644.
5. Soutschek, J.; Akinc, A.; Bramlage, B.; Charisse, K.; Constien, R.; Donoghue, M.; Elbashir, S.; Geick, A.; Hadwiger, P.; Harborth, J.; John, M.; Kesavan, V.; Lavine, G.; Pandey, R.K.; Racie, T.; Rajeev, K.G.; Rohl, I.; Toudjarska, I.; Wang, G.; Wuschko, S.; Bumcrot, D.; Koteliansky, V.; Limmer, S.; Manoharan, M.; Vornlocher, H.P. Therapeutic Silencing of an Endogenous Gene by Systemic Administration of Modified siRNAs. Nature 2004, 432, 173-178.
6. Allerson, C.R.; Sioufi, N.; Jarres, R.; Prakash, T.P.; Naik, N.; Berdeja, A.; Wanders, L.; Griffey, R.H.; Swayze, E.E.; Bhat, B. Fully 2′-Modified Oligonucleotide Duplexes with Improved In Vitro Potency and Stability Compared to Unmodified Small Interfering RNA. Journal of Medicinal Chemistry 2005, 48, 901-904.
7. Amarzguioui, M.; Holen, T.; Babaie, E.; Prydz, H. Tolerance for Mutations and Chemical Modifications in a siRNA. Nucleic Acids Research 2003, 31, 589-595.
8. Czauderna, F.; Fechtner, M.; Dames, S.; Aygun, H.; Klippel, A.; Pronk, G.J.; Giese, K.; Kaufmann, J. Structural Variations and Stabilising Modifications of Synthetic siRNAs in Mammalian Cells. Nucleic Acids Research 2003, 31, 2705-2716.
9. Chiu, Y.L.; Rana, T.M. siRNA Function in RNAi: A Chemical Modification Analysis. RNA 2003, 9, 1034-1048.
10. Harborth, J.; Elbashir, S.M.; Vandenburgh, K.; Manninga, H.; Scaringe, S.A.; Weber, K.; Tuschl, T. Sequence, Chemical, and Structural Variation of Small Interfering RNAs and Short Hairpin RNAs and the Effect on Mammalian Gene Silencing. Antisense and Nucleic Acid Drug Development 2003, 13, 83-105.
11. Morrissey, D.V.; Lockridge, J.A.; Shaw, L.; Blanchard, K.; Jensen, K.; Breen, W.; Hartsough, K.; Machemer, L.; Radka, S.; Jadhav, V.; Vaish, N.; Zinnen, S.; Vargeese, C.; Bowman, K.; Shaffer, C.S.; Jeffs, L.B.; Judge, A.; MacLachlan, I.; Polisky, B. Potent and Persistent In Vivo Anti-HBV Activity of Chemically Modified siRNAs. Nature Biotechnology 2005, 23, 1002-1007.
12. Braasch, D.A.; Jensen, S.; Liu, Y.; Kaur, K.; Arar, K.; White, M.A.; Corey, D.R. RNA Interference in Mammalian Cells by Chemically-Modified RNA. Biochemistry 2003, 42, 7967-7975.
13. Li, Z.Y.; Mao, H.; Kallick, D.A.; Gorenstein, D.G. The Effects of Thiophosphate Substitutions on Native siRNA Gene Silencing. Biochemical and Biophysical Research Communications 2005, 329, 1026-1030.
14. Elmen, J.; Thonberg, H.; Ljungberg, K.; Frieden, M.; Westergaard, M.; Xu, Y.; Wahren, B.; Liang, Z.; Orum, H.; Koch, T.; Wahlestedt, C. Locked Nucleic Acid (LNA) Mediated Improvements in siRNA Stability and Functionality. Nucleic Acids Research 2005, 33, 439-447.
15. Pham, J.W.; Sontheimer, E.J. Molecular Requirements for RNA-Induced Silencing Complex Assembly in the Drosophila RNA Interference Pathway. Journal of Biological Chemistry 2005, 280, 39278-39293.
16. Hohjoh, H. and RNA Interference (RNA(i)) Induction with Various Types of Synthetic Oligonucleotide Duplexes in Cultured Human Cells. FEBS Letters 2002, 521, 195-199.
17. Lamberton, J.S.; Christian, A.T. Varying the Nucleic Acid Composition of siRNA Molecules Dramatically Varies the Duration and Degree of Gene Silencing. Molecular Biotechnology 2003, 24, 111-120.
18. Christian, A.T.; Lamberton, J.S. Short Interfering Nucleic Acid Hybrids and Methods Thereof. 2004, WO 022771 A2.
19. Judge, A.D.; Sood, V.; Shaw, J.R.; Fang, D.; McClintock, K.; MacLachlan, I. Sequence-Dependent Stimulation of the Mammalian Innate Immune Response by Synthetic siRNA. Nature Biotechnology 2005, 23, 457-462.
20. Jackson, A.L.; Bartz, S.R.; Schelter, J.; Kobayashi, S.V.; Burchard, J.; Mao, M.; Li, B.; Cavet, G.; Linsley, P.S. Expression Profiling Reveals Off-Target Gene Regulation by RNAi. Nature Biotechnology 2003, 21, 635-637.
21. Brazas, R.M.; Hagstrom, J.E. Delivery of Small Interfering RNA to Mammalian Cells in Culture by Using Cationic Lipid/Polymer-Based Transfection Reagents. Methods in Enzymology 2005, 392, 112-124.
22. Chien, P.Y.; Wang, J.; Carbonaro, D.; Lei, S.; Miller, B.; Sheikh, S.; Ali, S.M.; Ahmad, M.U.; Ahmad, I. Novel Cationic Cardiolipin Analogue-Based Liposome for Efficient DNA and Small Interfering RNA Delivery In Vitro and In Vivo. Cancer Gene Therapy 2005, 12, 321-328.
23. Choudhury, A.; Charo, J.; Parapuram, S.K.; Hunt, R.C.; Hunt, D.M.; Seliger, B.; Kiessling, R. Small Interfering RNA (siRNA) Inhibits the Expression of the Her2/neu Gene, Upregulates HLA Class I and Induces Apoptosis of Her2/neu Positive Tumor Cell Lines. International Journal of Cancer 2004, 108, 71-77.
24. Rait, A.S.; Pirollo, K.F.; Ulick, D.; Cullen, K.; Chang, E.H. HER-2-Targeted Antisense Oligonucleotide Results in Sensitization of Head and Neck Cancer Cells to Chemotherapeutic Agents. Annals of the New York Academy of Sciences 2003, 1002, 78-89.
25. Rait, A.S.; Pirollo, K.F.; Xiang, L.; Ulick, D.; Chang, E.H. Tumor-Targeting, Systemically Delivered Antisense HER-2 Chemosensitizes Human Breast Cancer Xenografts Irrespective of HER-2 Levels. Molecular Medicine 2002, 8, 475-486.
26. Rait, A.S.; Pirollo, K.F.; Rait, V.; Krygier, J.E.; Xiang, L.; Chang, E.H. Inhibitory Effects of the Combination of HER-2 Antisense Oligonucleotide and Chemotherapeutic Agents Used for the Treatment of Human Breast Cancer. Cancer Gene Therapy 2001, 8, 728-739.
27. Kariko, K.; Buckstein, M.; Ni, H.; Weissman, D. Suppression of RNA Recognition by Toll-Like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA. Immunity 2005, 23, 165-175.
28. Pirollo, K.F.; Zon, G.; Rait, A.; Zhou, Q.; Yu, W. Hogrefe, R.I., and Chang, E.H. A Tumor Targeting Nanoimmunoliposome Complex for siRNA Delivery. Human Gene Therapy 2006, 17, 117-124.
29. Xu, L.; Huang, C.C.; Huang, W.; Tang, W.H.; Rait, A.; Yin, Y.Z.; Cruz, I.; Xiang, L.M.; Pirollo, K.F.; Chang, E.H. Systemic Tumor-Targeted Gene Delivery by Anti-Transferrin Receptor scFv-Immunoliposomes. Molecular Cancer Therapeutics 2002, 1, 337-346.
30. Xu, L.; Tang, W.H.; Huang, C.C.; Alexander, W.; Xiang, L.M.; Pirollo, K.F.; Rait, A.; Chang, E.H. Systemic p53 Gene Therapy of Cancer with Immunolipoplexes Targeted by Anti-Transferrin Receptor scFv. Molecular Medicine 2001, 7, 723-734.
31. Yu, W.; Pirollo, K.F.; Yu, B.; Rait, A.; Xiang, L.; Huang, W.; Zhou, Q.; Ertem, G.; Chang, E.H. Enhanced Transfection Efficiency of a Systemically Delivered Tumor-Targeting Immunolipoplex by Inclusion of a pH-Sensitive Histidylated Oligolysine Peptide. Nucleic Acids Research 2004, 32, e48.
32. Hawser, S.P.; Norris, H.; Jessup, C.J.; Ghannoum, M.A. Comparison of a 2,3-bis(2-Methoxy-4-Nitro-5-Sulfophenyl)-5-[(Phenylamino)Carbonyl] -2H-tetrazolium Hydroxide (XTT) Colorimetric Method with the Standardized National Committee for Clinical Laboratory Standards Method of Testing Clinical Yeast Isolates for Susceptibility to Antifungal Agents. Journal of Clinical Microbiology 1998, 36, 1450-1452.
33. Day, J.D.; Digiuseppe, J.A.; Yeo, C.; Lai-Goldman, M.; Anderson, S.M.; Goodman, S.N.; Kern, S.E.; Hruban, R.H. Immunohistochemical Evaluation of HER-2/neu Expression in Pancreatic Adenocarcinoma and Pancreatic Intraepithelial Neoplasms. Human Pathology 1996, 27, 119-124.
34. Apple, S.K.; Hecht, J.R.; Lewin, D.N.; Jahromi, S.A.; Grody, W.W.; Nieberg, R.K. Immunohistochemical Evaluation of K-ras, p53, and HER-2/neu Expression in Hyperplastic, Dysplastic, and Carcinomatous Lesions of the Pancreas: Evidence for Multistep Carcinogenesis. Human Pathology 1999, 30, 123-129.
35. Lieberman, S.M.; Horig, H.; Kaufman, H.L. Innovative Treatments for Pancreatic Cancer. Surgical Clinics of North America 2001, 81, 715-739.
36. Rabindran, S.K. Antitumor Activity of HER-2 Inhibitors. Cancer Letters 2005, 227, 9-23.
37. Luwor, R.B.; Lu, Y.; Li, X.; Mendelsohn, J.; Fan, Z. The Antiepidermal Growth Factor Receptor Monoclonal Antibody Cetuximab/C225 Reduces Hypoxia-Inducible Factor-1 Alpha, Leading to Transcriptional Inhibition of Vascular Endothelial Growth Factor Expression. Oncogene 2005, 24, 4433-4441.
38. Yu, W.; Pirollo, K.F.; Rait, A.; Yu, B.; Xiang, L.M.; Huang, W.Q.; Zhou, Q.; Ertem, G.; Chang, E.H. A Sterically Stabilized Immunolipoplex for Systemic Administration of a Therapeutic Gene. Gene Therapy 2006, 11, 1434-1440.
39. Khvorova, A.; Reynolds, A.; Jayasena, S.D. Functional siRNAs and miRNAs Exhibit Strand Bias. Cell 2003, 115, 209-216.
40. Ge, Q.; McManus, M.T.; Nguyen, T.; Shen, C.H.; Sharp, P.A.; Eisen, H.N.; Chen, J. RNA Interference of Influenza Virus Production by Directly Targeting mRNA for Degradation and Indirectly Inhibiting All Viral RNA Transcription. Proceedings of the National Academy of Sciences, USA 2003, 100, 2718-2723.
41. Allerson, C.R.; Bhat, B.; Eldrup, A.B.; Monoharan, M.; Griffey, R.H.; Baker, B.F.; Swayze, E.E. Compositions Comprising Alternating 2′-Modified Nucleosides for Use in Gene Modulation. US 2005/0187178 A1.
42. Nowotny, M.; Gaidamakov, S.A.; Crouch, R.J.; Yang, W. Crystal Structures of RNase H Bound to an RNA/DNA Hybrid: Substrate Specificity and Metal-Dependent Catalysis. Cell 2005, 121, 1005-1016.
43. Yang, W.; Wang, Q.; Howell, K.L.; Lee, J.T.; Cho, D.S.; Murray, J.M.; Nishikura, K. ADAR1 RNA Deaminase Limits Short Interfering RNA Efficacy in Mammalian Cells. Journal of Biological Chemistry 2005, 280, 3946-3953.
44. Yang, G.; Cai, K.Q.; Thompson-Lanza, J.A.; Jr., Bast, R.C.; Liu, J. Inhibition of Breast and Ovarian Tumor Growth Through Multiple Signaling Pathways by Using Retrovirus-Mediated Small Interfering RNA against Her-2/neu Gene Expression. Journal of Biological Chemistry 2004, 279, 4339-4345.
45. Faltus, T.; Yuan, J.; Zimmer, B.; Kramer, A.; Loibl, S.; Kaufmann, M.; Strebhardt, K. Silencing of the HER2/neu Gene by siRNA Inhibits Proliferation and Induces Apoptosis in HER2/neu-Overexpressing Breast Cancer Cells. Neoplasia 2004, 6, 786-795.
46. Urban-Klein, B.; Werth, S.; Abuharbeid, S.; Czubayko, F.; Aigner, A. RNAi-Mediated Gene-Targeting through Systemic Aapplication of Polyethylenimine (PEI)-Complexed siRNA In Vivo. Gene Therapy 2005, 12, 461-466.
47. McSwiggen, J.; Beigelman, L.; Pavco, P.; Fosnaugh, K.; Jamison, S. RNA Interference Mediated Inhibition of Epidermal Growth Factor Receptor (EGFR) Gene Expression Using Short Interfering Nucleic Acid (SINA). 2005, US 0176024 A1.
48. Ren, S.H.; Zhang, W.; Qu, P.; Liu, Y.; Wang, J.W.; Zhang, L. Effect of RNAi-Mediated Gene Silencing of C-erbB-2 on Proliferation of Lung Adenocarcinoma Cell Line calu-3. Ai Zheng 2005, 24, 1173-1178.
49. Moghimi, S.M.; Symonds, P.; Murray, J.C.; Hunter, A.C.; Debska, G.; Szewczyk, A. A Two-Stage Poly(Ethylenimine)-Mediated Cytotoxicity: Implications for Gene Transfer/Therapy. Molecular Therapy 2005, 11, 990-995.
50. Song, E.; Zhu, P.; Lee, S.K.; Chowdhury, D.; Kussman, S.; Dykxhoorn, D.M.; Feng, Y.; Palliser, D.; Weiner, D.B.; Shankar, P.; Marasco, W.A.; Lieberman, J. Antibody Mediated In Vivo Delivery of Small Interfering RNAs via Cell-Surface Receptors. Nature Biotechnology 2005, 23, 709-717.
51. Schiffelers, R.M.; Ansari, A.; Xu, J.; Zhou, Q.; Tang, Q.; Storm, G.; Molema, G.; Lu, P.Y.; Scaria, P.V.; Woodle, M.C. Cancer siRNA Therapy by Tumor Selective Delivery with Ligand-Targeted Sterically Stabilized Nanoparticle. Nucleic Acids Research 2004, 32, e149.
52. Jr., Landen, C.N.; Chavez-Reyes, A.; Bucana, C.; Schmandt, R.; Deavers, M.T.; Lopez-Berestein, G.; Sood, A.K. Therapeutic EphA2 Gene Targeting In Vivo Using Neutral Liposomal Small Interfering RNA Delivery. Cancer Research 2005, 65, 6910-6918.
53. Kunisawa, J.; Masuda, T.; Katayama, K.; Yoshikawa, T.; Tsutsumi, Y.; Akashi, M.; Mayumi, T.; Nakagawa, S. Fusogenic Liposome Delivers Encapsulated Nanoparticles for Cytosolic Controlled Gene Release. Journal of Controlled Release 2005, 105, 344-353.
54. Pal, A.; Ahmad, A.; Khan, S.; Sakabe, I.; Zhang, C.; Kasid, U.N.; Ahmad, I. Systemic Delivery of RafsiRNA Using Cationic Cardiolipin Liposomes Silences Raf-1 Expression and Inhibits Tumor Growth in Xenograft Model of Human Prostate Cancer. International Journal of Oncology 2005, 26, 1087-1091.